The application of mHealth to mental health: opportunities and challenges by Marsano, Lisa et al.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
King’s Research Portal 
 
DOI:
10.1016/S2215-0366(15)00268-0
Document Version
Peer reviewed version
Link to publication record in King's Research Portal
Citation for published version (APA):
Marsano, L., Bardill, A., Fields, B., Herd, K., Veale, D., Grey, N., & Moran, P. A. (2015). The application of
mHealth to mental health: opportunities and challenges. The Lancet Psychiatry, 2(10), 942-948. 10.1016/S2215-
0366(15)00268-0
Citing this paper
Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may
differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination,
volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are
again advised to check the publisher's website for any subsequent corrections.
General rights
Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright
owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.
•Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
•You may not further distribute the material or use it for any profit-making activity or commercial gain
•You may freely distribute the URL identifying the publication in the Research Portal
Take down policy
If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing details, and we will remove access to
the work immediately and investigate your claim.
Download date: 18. Feb. 2017
	 1	
 
 
 
 
VIEWPOINT 
The application of ‘mHealth’ to mental health: Opportunities and challenges 
 
Lisa Marzano1*, PhD, Andy Bardill1, PhD, Bob Fields1, PhD, Kate Herd1, PhD, David 
Veale2, MD, Nick Grey2, DClinPsych, and Paul Moran2, MD 
 
 
 
 
 
 
1 School of Science and Technology, Middlesex University, London, UK 
2 Institute of Psychiatry, Psychology and Neuroscience, King’s College London, UK 
 
* Please address correspondence to Dr Lisa Marzano, Psychology Department, Middlesex 
University, The Burroughs, London, NW4 4BT, UK. Email: l.marzano@mdx.ac.uk 
 
 
	 2	
ABSTRACT  
 
Recent advances in smartphones and wearable biosensors enable the gathering of 
‘real-time’ psychological, behavioural and physiological data, in increasingly precise 
and unobtrusive ways. It is therefore now possible to collect moment-to-moment 
information about an individuals’ moods, cognitions and activities, as well as 
automated data about their whereabouts, behaviour and physiological states.  In this 
paper, we discuss the potential of these new mobile digital technologies for 
transforming mental health research and clinical practice. By drawing on a recent 
research project, we illustrate how traditional boundaries between research and 
clinical practice are becoming increasingly blurred and how in turn, this is leading to 
exciting new developments in the assessment and management of common mental 
disorders. The potential risks and key challenges associated with applying mobile 
technology to mental health are also discussed. 
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1. INTRODUCTION 
Mobile digital technologies are increasingly able to gather multiple streams of real-
time behavioural, physiological and psychosocial data, in precise and unobtrusive 
ways. Examples of these technologies include smartphones, wearable biosensors, and 
more recently ‘smartwatches’. The range of personal data that can be gathered using 
such technology is truly vast, including personal accounts of affect, cognitions and 
behaviour, and objective/automated data about individuals’ whereabouts, activities 
and physiological states.  
 
Self-tracking mobile health applications (‘mHealth apps’) and wearable technology 
devices are now burgeoning in the consumer electronic market, and effectively 
creating a potential data goldmine for researchers interested in exploring disease 
mechanism. Some mobile technologies also potentially lend themselves to adoption as 
health technology interventions. In this paper, we discuss the potential of these new 
mobile digital technologies for transforming mental health research and clinical 
practice. By drawing on a recent research project, we illustrate how traditional 
boundaries between research and clinical practice are becoming increasingly blurred 
and how in turn, this is leading to exciting new developments in thinking about the 
assessment and management of common mental disorders.   
 
Are smartphones the research tools of the future?  
Research into psychopathology has traditionally relied on cross-sectional data, 
retrospective self-report and single-discipline approaches. However, the possibility of 
capturing a more fine-grained and dynamic picture of an individual’s emotional state 
and their experience of interacting with their environments is now well within our 
reach.   
 
Over the past twenty-five years, ambulatory assessment (AA) (1) and ecological 
momentary assessment (EMA) (2) methods – initially in the form of paper-and-pencil 
diaries, and then using increasingly sophisticated digital systems – have provided an 
important alternative to traditional research designs in clinical psychology and 
psychiatry, by capturing moment-to-moment information (most frequently about 
people’s moods and activities) within the flow of daily life. Within this research 
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paradigm, participants are followed for a period of time and complete questions at 
multiple points throughout the day. This reduces the likelihood of poor recall and 
allows the measurement of changes throughout the day, and in response to different 
events, activities, environments and biopsychosocial states.  
  
Within this methodological framework, smartphones are fast becoming “the central 
hub for ambulatory assessment” (1). Studies employing mobile digital technologies as 
research tools (‘mResearch’) offer some distinct advantages, not only over traditional 
research and assessment approaches, but also in comparison to other AA devices. For 
instance, EMA research has tended to use highly structured formats, with the aim of 
gathering robust longitudinal quantitative and “self-quantifying” data. Yet, 
smartphone technology is also ideally suited to yield rich user-driven data, including 
naturalistic speech, audio and visual data. Such data can provide crucial insights into 
the meaning, context, and functions of people’s emotional states, activities and 
behaviour. Compared to more traditional research methods, mobile technology 
enables research participants to tell their stories in their own time and space, thus 
overcoming some the difficulties associated with collecting sensitive information by 
personal interview. Such technology also gives participants the freedom to decide and 
personalize how to record their thoughts; some may prefer to write about their 
experiences, others to talk about them, or to document them using photos or videos. 
Video-diaries and digital ethnographic methods offer another promising avenue for 
mental health research, as they also allow participants to generate a wealth of non-
verbal data, and permit use of images and audio/video-clips to disseminate research 
findings, potentially widening their accessibility and impact.  
 
Further potential of mResearch rests in the ability to gather a wealth of automated 
data, i.e., multi-dimensional, user-centred data that are not exclusively reliant on self-
report. These data do not just potentially triangulate participant self-report but can 
also provide important insights into mechanisms implicated in the development and 
maintenance of psychiatric disorders. For example, regulation of negative affect is 
thought to be both an underlying and reinforcing mechanism for repeat self-harm (3). 
Yet, it is very challenging to accurately capture this relying wholly on self-report (4). 
A multi-dimensional data gathering system, which captures biomarkers of autonomic 
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reactivity, as well as self-report accounts of emotional states - in real-time and in 
naturalistic settings - is likely to provide a fine-grained and ecologically-valid picture 
of an individual’s emotional state and associated behaviour.  
 
Automated information about users’ location and mobility, sleep quality and duration, 
and social context can further enrich these data, allowing for a better understanding of 
where, when and possibly why individuals experience a range of symptoms and 
behaviours at any particular point in time. This issue may be particularly germane in 
relation to individuals who experience difficulties with verbal communication, self-
disclosure and autobiographical memory retrieval. 
 
There is an established tradition of ambulatory physiological assessment and 
observational monitoring in behavioural medicine and clinical psychology, but 
traditional devices for observational and physiological AA have tended to target only 
one form of activity or information (e.g., acoustic information or physical activity or 
heart rate variability, etc.), and have been relatively expensive and often burdensome 
to wear, thus increasing their potential intrusiveness and the likelihood of reactivity 
effects (see Trull & Ebner-Priemer (2013) (1) for a comprehensive review). These 
factors, as well as power and storage limitations, have meant that most AA 
psychophysiological studies have lasted only 24 to 48 hours.  
 
However, now, all these data can be readily collected by the sensors on a modern 
smartphone (5), and also on compatible sleep and activity-tracking devices such as 
Jawbone (6) and Fitbit (7), as well increasingly sophisticated smartwatches. Whilst 
mostly designed for the consumer market, these devices may also be usefully adopted 
in research aiming to understand complex psychological processes over long periods 
of time. Smartphones and smartphone-supported biosensors are multifunctional, 
relatively inexpensive, and have high general market penetration. An important 
advantage is that they are typically carried/worn by users throughout the day and if 
necessary also at night. This contributes to their potential as powerful and relatively 
unobtrusive research tools.  
 
In addition, the application of these devices for research purposes potentially 
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facilitates data collection from ‘hard-to-reach’ populations.  To use the example of 
self-harm again, young people who self-injure may feel uncomfortable discussing 
their feelings and behavior in a one-to-one interview situation, or find it difficult to 
verbalise what triggers or maintains their self-harming behavior. They may however 
be more willing to engage with a well-designed digital diary or blogging study (an 
example is the ‘Day in the Life’ Project, a blogging study aiming to capture everyday 
experiences of people living with mental health difficulties - see 
https://dayinthelifemh.org.uk/).  
 
Smartphones and EMA add-on tools are increasingly being used to investigate 
mechanisms and phenomenology of psychopathology, including in psychotherapeutic 
contexts and treatment settings, as well as in psychopharmacological trials (8). A 
recent review of this literature suggests that the use of EMA techniques in mood 
disorder research (including via mobile technologies) is “feasible, generally 
acceptable, and highly promising” (9). Other work has focused on the use of EMA to 
investigate symptoms of borderline personality disorders (10), anxiety disorders (11), 
and mental illness more generally (12), and similarly concluded that despite some 
inherent challenges, this approach offers several advantages. Yet, previous 
experimental attempts to collect and analyse data using mobile digital technologies 
have been relatively limited in scope, mostly relying on quantitative self-report 
(mainly of mood and activities via patient reported outcome or experience measures) 
and/or employing a simple collection of sensing and monitoring technologies, in 
selected diagnostic groups (e.g., unipolar (13) or bipolar depression (14)). We 
therefore argue that the potential of these new technologies is yet to be fully explored 
and evaluated.  
 
2. LESSONS FROM RESEARCH 
INdividual SIGnals mHealth Technology - the INSIGHT Study 
To assess the feasibility of researching a range of emotional symptoms and 
behavioural disturbance using smartphones and wearable biosensors, we developed 
and tested a prototype system (‘INSIGHT’ (15)) that allows real-time gathering of 
multiple streams of quantitative and qualitative data (including audio/video clips and 
still images), through a variety of sources and devices:  
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• A smartphone application (“app”) recording location data and distance 
travelled, that also allowed participants to complete a regular multi-media 
diary (“My Diary”) of a) daily moods and activities, b) intensity, duration and 
contextual features of maladaptive thoughts and behaviour, c) other risk-
taking and impulsive behaviours, d) flashbacks, and e) nightmares. The app 
was also linked to a secure Wordpress Blogging site (also available to 
participants on other devices, e.g. PCs, tablets), where participants could post 
pictures, videos and text about their broader life histories and experiences, as 
well as record daily moods and activities (“My Story”).  
• Jawbone Up wristband, recording physical activity, sleep quality and duration.  
• Chest strap and custom-made wearable data logger for continuous 
measurement of heart   rate (and heart rate variability).  
 
[Insert figure 1 about here] 
 
With a view to testing the utility and feasibility of this system on a common and 
serious behavioural problem, we focused our efforts on charting self-harming 
behaviour in a small group of men (n=5) recruited via a voluntary organization that 
supports individuals with personality disorders. Recruitment followed initial 
consultations with staff and service users about the nature of the study.  Four 
participants were identified via staff referrals and a fifth participant came forward at a 
later stage, having heard about the research at the centre.  All volunteers were over the 
age of 18.  In light of the small sample, we are unable to comment on the 
generalisability of findings, yet some interesting points emerged. Firstly, compliance 
with our battery of measures was excellent. All participants took part in the study for 
at least three weeks (this was the study duration originally agreed with participants; 
one man volunteered to continue the study for an additional 28 days; another 
participants took part in the study for a total of 79 days). During this time, participants 
could make as many “My diary” and “My Story” entries as they wished. In total, 
participants made 230 “My Diary” entries, with all participants making at least one 
entry on most days, and 209 “My Story” entries (these were mostly text-based, but 
included 34 videos and eight photos). Participants’ “My Diary” entries provided 
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information about 92 episodes involving thoughts of self-harm and 21 separate 
incidents of self-harming behaviour (16).  
 
It is notable that there was no financial incentive for participating in the study and it 
would appear that at least in this small group, making the entries was a sufficient 
incentive in its own right.   
 
Another promising finding from our pilot study was that the experience of completing 
the battery was overwhelmingly positive for all participants. They all reported that the 
experience had been personally beneficial, meaningful and not inconvenient, despite 
some initial anxieties about damaging the technology or failing to operate it properly. 
Clearly, for some individuals, the process of gathering ecologically valid data may 
alone have vicarious therapeutic effects. Amongst the benefits mentioned by 
participants were the possibility of expressing one’s feelings in a safe way, including 
when surrounded by other people (“who assume you are just on Facebook or 
texting”); helping them learn about themselves and “see patterns” in their thoughts 
and behaviours; and showing the video-diaries to their therapist, “so they can see 
what I am actually like when I'm feeling depressed and down”. All the participants 
reported that they had gained insight into their experiences through research 
participation and there did not appear to be any significant adverse effects in relation 
to triggering self-harming thoughts or behaviour (16).  
 
Our observation that the INSIGHT system may have had some beneficial effects 
raises an important question about the boundaries between observational research and 
clinical intervention. Gathering real-time data from vulnerable participants in their 
daily lives may have blurred these boundaries, arguably more so than in traditional 
mental health research. We were ethically bound to regularly monitor participants’ 
well-being (mostly by monitoring their “My Diary” and “My Story” entries), and 
intervene where necessary. This meant working in close collaboration with a clinical 
service that advised on the suitability of potential participants for the study, and 
provided appropriate care and crisis support as required. This is potentially an 
example of where mHealth could act as a useful ‘early warning system’ for clinical 
teams.  In addition, the prospect of self-monitoring and being monitored is likely to 
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have also had an impact on participants’ symptoms, or at least on how these were 
experienced and reported.  In other words, digital monitoring will inevitably have a 
“Hawthorne effect” - the size and therapeutic (or anti-therapeutic) nature of such an 
effect has yet to be quantified.    
 
3. MULTI-DIMENSIONAL REAL-TIME MONITORING OF EMOTION AND 
BEHAVIOUR - FROM mRESEARCH TO mHEALTH  
As the study progressed, it became increasingly apparent that system that was 
originally conceived and developed as a data collection tool may also have clinical 
utility. Patient-led monitoring of symptoms is now standard practice in many areas of 
medicine and serves a wide variety of functions, from monitoring of symptom 
severity (e.g. blood glucose testing in diabetes, or anxiety and depression symptoms 
monitoring in CBT treatment services) through to monitoring of treatment side 
effects.  
 
Previous research has shown that repeated self-monitoring can have therapeutic 
effects for mood and anxiety disorders (17, 18), possibly by improving insight into the 
longitudinal course of symptoms which in turn allows the identification  of 
personalized ‘relapse signatures’. Monitoring of context, antecedents and 
consequences is key in functional analyses of maladaptive behaviours and cognitive 
processes, and thus potentially instrumental in modifying behaviour (19). Moreover, 
if it occurs in real-time, it can shape timely personalised interventions, including 
behavioural prompts to highlight vulnerability and to encourage alternative 
behaviours (e.g. via behavioural activation for depressive symptoms and mindfulness-
based exercises to enhance emotion regulation and distress tolerance) (20, 21). 
However, in the area of mental health, symptom and behavioural monitoring are 
generally performed retrospectively and reliant on self-report. As such, they are 
subject to recall bias, and limited in their ability to facilitate real time feedback and 
clinical intervention when a warning trigger is identified.  
 
Using recent technologies along with novel data visualisation and analysis tools, it is 
not only possible to monitor psychiatric symptoms in real time and in naturalistic 
settings, but also to combine heterogenous datasets, for functional analyses and real-
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time dynamic risk assessment. In turn, these can help identify a sequence of events, 
emotions and behaviours preceding and following dysfunctional behaviour. For 
example, using data from our INSIGHT pilot study, we were able to visualise a broad 
range of data over time, including automated measures (e.g. activity, sleep quality, 
heart rate and variability), subjective measures (e.g. responses to questions about 
affective state) as well as discrete events (e.g. reports of self harm) (figure 2), and 
participants’ locations logged by the smartphone app, overlaid on a map (figure 3).  
The chart also allows filtering and zooming, to investigate more specific patterns and 
relationships (figure 4), and can be refined to link quantitative data (both automated 
and self-report) with audio/video clips and still images in which participants record 
and reflect on their symptoms and experiences. Such visual analyses can inform and 
enrich time series statistical models to reveal sequential dependencies between 
maladaptive behaviours and other key variables (e.g. mood, sleep, location, etc.) both 
within and between subjects. This may greatly increase understanding of the 
psychophysiological processes and mechanisms underpinning common mental 
disorders, and has the potential to unlock new therapeutic avenues.  Further work is 
needed to establish the optimal components of INSIGHT, in terms of their individual 
and collective ability to map on to clinical relapse - bearing in mind the idiographic 
focus of EMA assessment (1).  
 
 [Insert figures 2-4 about here] 
 
Subject to further testing and development, our digital data gathering system may 
function as a useful transdiagnostic tool for a) multi-dimensional and multi-media 
monitoring; b) real-time feedback (via data visualisations which users can share with 
their clinicians); and c) timely personalized intervention, when a relapse signature or 
early warning trigger is detected by the user, a clinician or even the system itself. The 
latter may include interventions delivered (at least partly) using smartphones, such as 
real-time supportive and psycho-education messaging or verbal feedback; medication 
and appointment reminders, bio-feedback, and a range of self-management tools. 
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mHealth: the future of mental healthcare? 
We are not alone in supporting the case for integrating technological innovations in 
psychiatric treatment and research. Health-related smartphone applications and 
wearable biosensors are increasingly being seen as viable and cost-effective solutions 
to enhance clinical practice and improve treatment accessibility via mobile and 
‘connected’ healthcare (22–26). This includes online and text messaging systems for 
monitoring and self-management of psychiatric symptoms, and a growing number of 
commercial mood tracking and diary ‘apps’. Notable examples are "True Colours", 
"Buddy" and "Careloop", which allow users and clinicians to monitor symptoms and 
experiences using text, email and the internet; "Health Mapper", for smartphone-
monitoring of a variety of health conditions; and self-help apps for stress, anxiety and 
associated urges and behaviours, such as "SAM", the "Stress and Anxiety 
Companion", "iCope", "DBT Coach" and "The Mindfulness App". 
 
mHealth is a rapidly expanding field, and evidence of clinical effectiveness is 
currently limited (27). Assessment of efficacy and effectiveness is partially hampered 
by the challenge of evaluating rapidly evolving technology (28, 29). Nevertheless, an 
increasing number of studies suggest that there is sufficient theoretical underpinning 
and mounting evidence on the safety and acceptability of mHealth – supporting the 
greater use of technological innovations in mental healthcare (22), including for 
individuals with severe mental illness (30). High-level enthusiasm for this is reflected 
in recent government plans to introduce NHS accreditation and ‘kitemarking’ of 
health and wellbeing smartphone apps and digital services (31), and also in a recent 
report from the Chief Medical Officer (22), which stressed the need for “a strong 
emphasis on co-design and user needs as a key driver”. If mHealth interventions are 
to be effectively incorporated into existing treatment processes, such ‘users’ should 
also include clinicians. 
 
mHealth technologies, be they standalone apps or more complex systems 
incorporating wearable biosensors and self-tracking technologies, can collect 
exquisitely rich data about individual cases, in considerably greater volume than has 
been previously achieved.  Over time, these data may make an important contribution 
towards our understanding of the psychophysiological processes underpinning mental 
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disorders. The existence of such data also creates a very tangible form of ‘precision 
psychiatry’ for individual patients. As argued by Insel (2014), “data mining can now 
begin to identify the links across levels, including the factors that will yield categories 
predicting prognosis or treatment response for individual patients”. Eventually this 
approach may help “create a matrix of information for individual patients, leading 
ultimately to precision medicine for psychiatry” (32). 
 
Risks and the need for regulation 
There are naturally risks, as well as clinical and scientific opportunities associated 
with mHealth.  In a rapidly expanding and largely unregulated field, existing mHealth 
systems and apps vary greatly in quality and scope. A recent systematic review 
identified only five apps that had been tested for clinical effectiveness (of which only 
two were available in ‘app stores’) amongst the over 3,000 mental health apps 
available for public download at the time of the research (27). In the UK, the NHS 
Health Apps Library contains (as of 10 May 2014) 27 apps categorised under mental 
health, having been reviewed by a clinical assurance team. This is almost 50% more 
than a year ago (22), but remains a very small proportion of the commercially 
available apps - for which there is currently no mechanism of quality control. An 
encouraging development in the field is the imminent publication of guidelines on the 
development of commercial health and well-being apps by the British Standards 
Institution. Nevertheless, it remains to be seen whether these voluntary standards will 
ultimately mean compliance with EU Medical Device Directives. 
 
Further areas of concern are the risk of reinforcing inequalities and the so-called 
‘digital divide’ (33); and of placing excessive emphasis on self-help in the immediate 
absence of evidence about effectiveness. In addition, there are important unanswered 
questions about whether and how data gathered via clinical or commercial mHealth 
tools can or should be used for research purposes, and, if so, how this process should 
be regulated.  
 
There are certainly precedents of anonymised individual patient data - collected for 
clinical purposes - being used for research and service evaluation purposes (a recent 
example in England is the IAPT (Improving Access to Psychological Treatment) 
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database (34)). However, there are also precedents of personal data being collected by 
consumer apps and ‘smart’ technologies which have then been used, without explicit 
consent, for marketing, commercial and other purposes. Individual consent and 
confidentiality concerns need to be addressed, as well as the compliance of new 
systems to key governance arrangements, such as the Data Protection Act, European 
Data Protection Regulation, copyright and licencing laws. The use of e-data from 
mental health users has recently provoked discontent amongst users (35), and so these 
matters demand wider and urgent debate. Such debate will hopefully maximise the 
likelihood that services users are only exposed to novel mHealth technologies that are 
scientifically robust, safe, clinically effective and respectful of an individual’s 
privacy. 
 
Design and Clinical Challenges   
Key challenges remain in developing the full potential of these technologies as 
adjuncts to clinical practice. These challenges principally relate to interaction, 
automation and ‘blending’ - i.e., the degree to which these technologies can and 
should be interactive, ‘intelligent’ and suitable for use as standalone interventions.  
 
Multiple heterogenous datasets can be gathered and visualised, but without 
interpretation, these data lack meaning for patients, clinicians and researchers. 
Enabling effective interpretation, and hence productive intervention, is reliant upon 
developing methods and tools for data visualisation and interaction with the data that 
support clinical practice.  Ideally, data visualisation should be contextually sensitive, 
individualised to the required degree and readily understandable to the end-user.  This 
is a multidisciplinary challenge and one which is likely to be best met through a 
careful process of co-design. 
 
There is also an important conversation to be had about the extent to which mHealth 
systems should rely solely on automation and ‘machine learning’. The ability of such 
systems to help us define clear relapse signatures has a seductive appeal.  
Nevertheless, there is an inherent danger in becoming over-reliant on IT system 
intelligence. In addition, the use of complex technological systems may make patients 
and clinicians feel disconnected from one another. Decisions and approaches about 
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what to automate, when to automate it and why are not known, nor is there currently 
sufficient evidence to guide us about how and when patients should receive feedback 
about changes in their emotional state or potential risk of relapse. These are all 
empirical questions which need to be researched. 
 
Further research is also needed to determine which patient groups benefit from 
mHealth as a stand-alone feature, and which groups would derive greater benefit from 
mHealth being delivered as an adjunct to face-to-face contact with a clinician. This is 
likely to be determined by severity of distress and the level of functional impairment.  
It is indeed possible that a sliding scale of 'blending' may develop over time, 
potentially mirroring the stepped care approach adopted by IAPT (36).  
 
4. CONCLUSION 
The field of digital healthcare is new and expanding rapidly. A number of key 
challenges lie ahead. Further pilot and feasibility studies are required in order to 
establish which emotional and behavioural features and which patient populations 
derive the greatest benefit from mHealth monitoring.  Such piloting may also provide 
indicative effect estimates for the possible therapeutic value of mHealth monitoring.  
Appropriate quality control and governance arrangements are urgently needed in 
order to assure the public about key matters relating to safety and privacy.  Subject to 
these matters being satisfactorily dealt with, the efficacy of these new technologies 
will require testing in appropriate designs – ideally in large randomised controlled 
trials (RCTs), but other designs may also be appropriate. As digital technologies 
allow for intensive measurement over time, and given the contemporary focus on 
individualised medicine, Single Case Experimental Designs (SCEDs) may be 
particularly useful for making causal inferences about mHealth interventions, as well 
as being more more time- and cost-effective than RCTs, and offering some important 
advantages in terms of internal and external validity (37-39). 
  
Digital technologies create a new set of opportunities as well dilemmas, as the 
boundaries between research, monitoring and clinical intervention become 
increasingly blurred. Whilst this creates the possibility of true paradigm shifts, it also 
reinforces the need for researchers, clinicians and service users to work in close 
	 15	
collaborative partnership to test the efficacy, safety and acceptability of the new 
technologies that we have at our disposal. 
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Search strategy and selection criteria 
References for this Personal View were identified through searches of PubMed and 
PsycINFO for articles published from January, 1980, to March, 2015, by use of the 
terms "ecological momentary assessment", “experience sampling”, "ambulatory 
assessment", “smartphone”, “mHealth”, “connected health”, “psychopathology” and 
"mental health". Further targeted searches were undertaken with Google Scholar. 
Articles resulting from these searches and relevant references cited in those articles 
were reviewed. Only articles published in English were included. 
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